NAD Supplementation to Reduce the Incidence of Cardiac Surgery Associated Acute Kidney Injury

Sponsor
Beth Israel Deaconess Medical Center
Study ID
NCT07739290
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Acute Kidney Injury

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Nicotinamide (NAM) — DIETARY_SUPPLEMENT
    A one time 3000 mg nicotinamide dose administered orally on the morning of cardiac surgery
  • Placebo control — DIETARY_SUPPLEMENT
    A visually identically placebo

Study Details

The purpose of this single-center, randomized, double-blinded placebo-controlled pilot trial is to demonstrate feasibility and help design a larger trial to assess the effectiveness of nicotinamide (NAM) supplementation in reducing risk of post-operative AKI in patients undergoing cardiac surgery.

Key Dates

First listed
Jul 31, 2026
Start date
Sep 1, 2026
Status verified
Jul 2026
Primary completion
Oct 1, 2028
Completion
Jan 1, 2029

Study Design

Enrollment
20 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION

Arms

  • Experimental: Intervention Group - Nicotinamide
    3000 mg nicotinamide administered the morning of surgery
  • Placebo Comparator: Control
    Placebo administered orally the morning of surgery

Primary Outcome Measure

Post Operative day 1 urinary KIM-1 [ Time Frame: From enrollment to 1 day post cardiac surgery ]

Central Contacts

Related Studies